

Clinical Expert Summary
Aviptadil/phentolamine mesilate (Invicorp[®]) 25 micrograms/2 mg solution
for injection

Aviptadil/phentolamine mesilate (Invicorp[®]) for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology

1. Existing guidelines

Experts did not highlight any guidelines that influence prescribing in this area.

2. Disease prevalence/incidence

Although it was agreed that erectile dysfunction affects large numbers of men, it was noted that the exact prevalence of erectile dysfunction is difficult to estimate: published studies of prevalence exist, but these have varying results. Additionally, it was estimated that erectile dysfunction affects 60% of men with coronary artery disease, 55% of men with hypertension, and 50–75% of men with diabetes.

3. Current treatment options

The following current treatment options were highlighted:

- PDE5 inhibitors
- Prostaglandins
- Vacuum pumps
- Penile prosthesis

4. Unmet needs

It was highlighted that for patients with severe erectile dysfunction, the simpler modalities of managing the condition are often unhelpful or sub-optimal. Other modalities of treatment are therefore needed to treat all patients successfully.

5. Knowledge of product in given indication

It was envisaged that aviptadil/phentolamine would be most suitable as an option where first-line treatment with PDE5 inhibitor(s) has failed.